Learning Center

Your central location for online learning and education surrounding all aspects of tissue donation, tissue banking, research and transplantation.

Back to Search by Speaker

Aaron Schieving

Aaron Schieving

Vice President, Sales and Marketing

Aaron Schieving joined Lifecycle Biotechnologies in 2015 and as the VP, Sales and Marketing is responsible for the strategic development and management of the brands under the Lifecycle umbrella, Boval BioSolutions; a biologics manufacturing site, Chata Biosystems; a chemical, reagent, and media manufacturing site, and VI Plastics; a blow mold plastics manufacturing site. In this role Mr. Schieving also provides technical consultations on behalf of Boval, Chata, and VI Plastics focused on driving process improvements for each company’s customers. Mr. Schieving also serves as a member of the Lifecycle executive team. Previously, Mr. Schieving held roles with LABS, Inc. and Nelson Laboratories. Mr. Schieving's expertise spans multiple industries such as medical device, pharmaceuticals, organ and tissue, cell therapy and regenerative medicine and included advanced knowledge in microbiology and sterilization. Over the years Mr. Schieving has participated in numerous AATB committees and workgroups, include the Scientific Technical Affairs Committee (STAC), the Program Committee, and the Birth Tissue Workgroup.

Content Where I Am Featured

Sort By
  • Contains 2 Component(s), Includes Credits

    Human organ and tissue donors must be screened to determine their eligibility to donate, and to ensure that the human cells and tissues to be transplanted are free from communicable disease agents. Tissues are also tested to ensure patient safety from objectionable organisms. How can you be certain your suppliers aren’t making these requirements harder for you to meet? In this presentation we will cover a case study that impacted the Pharmaceutical industry involving supplier contamination, the results from that contamination, and the risk mitigation steps put in place. Through benchmarking another highly regulated industry we can learn valuable lessons to prevent similar supplier contamination in order to ensure optimal recipient outcomes and to avoid unnecessary processing requirements.